Question: What are the economic implications of using a noninvasive gene expression test (the pigmented lesion assay) to rule out melanoma and the need for surgical biopsy of atypical pigmented lesions suggestive of melanoma? Findings: In this cost-savings analysis of the pigmented lesion assay using model inputs for patients with pigmented lesions suggestive of melanoma, a $447 (47%) cost reduction per assessed pigmented lesion vs the current histopathologic standard of care was achievable if the assay was priced at $500.
Pediatric Spitz nevi pose significant diagnostic challenges to physicians and dermatopathologists with the current image-recognition based standard. In this clinical study, gene expression patterns of pigmented lesions from FFPE tissue block samples were investigated.
Not missing melanomas in daily practice keeps dermatologists up at night and is a challenge even for dermatologists who see pigmented lesion cases regularly.
BCC-SCC 2018 AAD ABSTRACT
Validation of Non-Invasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS and TERT) in Cutaneous Melanoma
Late Breaking Abstract- AAD2018